Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, non-randomized, single-dose, parallel-group study. Each subject will
receive a subcutaneous dose of MNTX. Eight subjects with normal hepatic function and eight
subjects from each classification of hepatic impairment will be enrolled. Plasma samples will
be collected before and at specified intervals after dosing and the concentration of MNTX
will be analyzed.
Phase:
Phase 1
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.